80 related articles for article (PubMed ID: 36098872)
1. Teserpaturev/G47Δ: First Approval.
Frampton JE
BioDrugs; 2022 Sep; 36(5):667-672. PubMed ID: 36098872
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.
Hu M; Liao X; Tao Y; Chen Y
Front Immunol; 2023; 14():1352909. PubMed ID: 38187372
[TBL] [Abstract][Full Text] [Related]
3. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Issues: PMDA - Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma.
Maruyama Y; Sakurai A; Noda S; Fujiwara Y; Okura N; Takagi T; Asano J; Honda F
Oncologist; 2023 Aug; 28(8):664-670. PubMed ID: 36917020
[TBL] [Abstract][Full Text] [Related]
6. Developing Oncolytic Viruses for the Treatment of Cervical Cancer.
Kalafati E; Drakopoulou E; Anagnou NP; Pappa KI
Cells; 2023 Jul; 12(14):. PubMed ID: 37508503
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy: basic principles, recent advances and future directions.
Lin D; Shen Y; Liang T
Signal Transduct Target Ther; 2023 Apr; 8(1):156. PubMed ID: 37041165
[TBL] [Abstract][Full Text] [Related]
8. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
9. Viral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification.
LaRocca CJ; Jacobsen KL; Inoko K; Zakharkin SO; Yamamoto M; Davydova J
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515182
[TBL] [Abstract][Full Text] [Related]
10. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
Gujar S; Pol JG; Kumar V; Lizarralde-Guerrero M; Konda P; Kroemer G; Bell JC
Nat Protoc; 2024 May; ():. PubMed ID: 38769145
[TBL] [Abstract][Full Text] [Related]
11. CD8
Chen Y; Yu D; Qian H; Shi Y; Tao Z
J Transl Med; 2024 Apr; 22(1):394. PubMed ID: 38685033
[TBL] [Abstract][Full Text] [Related]
12. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cellular therapy: revolutionizing adoptive cellular therapy.
Xu MY; Zeng N; Liu CQ; Sun JX; An Y; Zhang SH; Xu JZ; Zhong XY; Ma SY; He HD; Hu J; Xia QD; Wang SG
Exp Hematol Oncol; 2024 Apr; 13(1):47. PubMed ID: 38664743
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel, high-efficacy oncolytic herpes simplex virus type 1 platform equipped with two distinct retargeting modalities.
Joo HY; Baek H; Ahn CS; Park ER; Lee Y; Lee S; Han M; Kim B; Jang YH; Kwon H
Mol Ther Oncol; 2024 Mar; 32(1):200778. PubMed ID: 38596302
[TBL] [Abstract][Full Text] [Related]
15. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
16. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cell (MSC)-Based Drug Delivery into the Brain across the Blood-Brain Barrier.
Tashima T
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399342
[TBL] [Abstract][Full Text] [Related]
18. Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.
Ageenko A; Vasileva N; Richter V; Kuligina E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396720
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
Victorio CBL; Novera W; Ganasarajah A; Ong J; Thomas M; Wu J; Toh HSY; Sun AX; Ooi EE; Chacko AM
J Transl Med; 2024 Feb; 22(1):126. PubMed ID: 38308299
[TBL] [Abstract][Full Text] [Related]
20. Progress in oncolytic viruses modified with nanomaterials for intravenous application.
Chen L; Ma Z; Xu C; Xie Y; Ouyang D; Song S; Zhao X; Liu F
Cancer Biol Med; 2023 Nov; 20(11):830-55. PubMed ID: 38009779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
